CEL-SCI (NYSE:CVM) Trading Down 4.4% – Should You Sell?

CEL-SCI Co. (NYSE:CVM) shares traded down 4.4% on Monday . The stock traded as low as $0.69 and last traded at $0.70. 570,844 shares changed hands during mid-day trading, a decline of 10% from the average session volume of 636,752 shares. The stock had previously closed at $0.73.

Wall Street Analysts Forecast Growth

Separately, StockNews.com downgraded CEL-SCI from a “hold” rating to a “sell” rating in a report on Wednesday, November 20th.

CEL-SCI Stock Down 4.4 %

The stock has a market cap of $44.54 million, a price-to-earnings ratio of -1.20 and a beta of 0.59. The firm has a 50 day simple moving average of $0.73 and a two-hundred day simple moving average of $1.01. The company has a debt-to-equity ratio of 1.00, a current ratio of 0.64 and a quick ratio of 0.18.

Institutional Investors Weigh In On CEL-SCI

Several large investors have recently made changes to their positions in the stock. Calton & Associates Inc. acquired a new stake in shares of CEL-SCI in the 3rd quarter valued at approximately $50,000. Black Diamond Financial LLC increased its position in CEL-SCI by 35.8% during the second quarter. Black Diamond Financial LLC now owns 72,000 shares of the company’s stock worth $84,000 after buying an additional 19,000 shares during the last quarter. Plotkin Financial Advisors LLC acquired a new stake in shares of CEL-SCI in the third quarter valued at approximately $98,000. Cutter & CO Brokerage Inc. boosted its stake in shares of CEL-SCI by 29.4% during the 2nd quarter. Cutter & CO Brokerage Inc. now owns 108,445 shares of the company’s stock worth $126,000 after acquiring an additional 24,634 shares during the period. Finally, Thoroughbred Financial Services LLC raised its stake in CEL-SCI by 140.9% in the 2nd quarter. Thoroughbred Financial Services LLC now owns 136,761 shares of the company’s stock valued at $158,000 after acquiring an additional 80,001 shares during the period. Institutional investors own 12.08% of the company’s stock.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.